subscribe: Posts | Comments | Email

Canada Based Start-up BufferBox Acquired by Google

1 comment

On Friday, New York based OnlineMediaDaily, the declared largest and most influential media, marketing and advertising online site on the net, reported that Waterloo Ontario based startup BufferBox will be acquired by Google primarily for its network of physical parcel pick-up station capabilities.  The media outlet quotes a Google spokesperson as indicating that the global information content and services provider, with this acquisition, wants to remove as much friction from the shopping experience as possible. BufferBox an early-stage startup and its web site notes that after launching a very successful pilot at the University of Waterloo, the start-up focused efforts on rolling out a network of pick-up stations across the Greater Toronto Area.  BufferBox founders also acknowledge the acquisition by Google on their web site. In March of this year, Supply Chain Matters noted that Google was making plans to offer a variety of co-branded tablet computers directly to consumers […]

U.S. FDA Begins to Initiate Increased Regulatory Powers- A Painful Awareness for Industry Players

1 comment

If producers of pharmaceutical of food products had any doubts as to the new powers and extended reach of the U.S. Food and Drug Administration (FDA) under the 2011 extended food safety law, there was ample evidence demonstrated last week. India based generics drug producer Ranbaxy Pharmaceuticals Inc. was forced to voluntarily halt production of the generic equivalent of the highly utilized cholesterol drug Lipitor while it continues to investigate how tiny glass particles were introduced in some production batches. According to various syndicated business and social media reports, the recall was due to “possible contamination with very small glass particles similar to the size of a grain of sand.” The suspension involves certain lots of the 10mg, 20mg and 40mg dosage strengths of atorvastatin tablets, according to the FDA. The FDA took the step of halting the production of foreign produced Ranbaxy generic atorvastatin from the extended powers granted […]